Metrics Names Wes Edwards Chief Financial Officer
Edwards will oversee company's financial, logistical and human-resources operations.
Contract pharmaceutical developer and manufacturer Metrics Inc. has appointed Wes Edwards, MBA, CPA, as its chief financial officer. Edwards brings to Metrics 15 years of corporate and military experience in finance, accounting, supply chain management and pricing. He will oversee the company’s financial, logistica, and human-resources operations.
Last year, the privately held Metrics was acquired by Mayne Pharma Group Limited, a corporation publicly traded on the Australian Securities Exchange (ASX). Going public means Metrics now interacts with newfound stakeholders – such as regulators and investors – who have clear expectations when it comes to financial disclosure, said Phil Hodges, president of Metrics Inc.
Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. Their areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical trial material (CTM) manufacturing for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.
Source: Metrics Inc.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
